| Product Code: ETC4640082 | Publication Date: Nov 2023 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 60 | No. of Figures: 30 | No. of Tables: 5 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Taiwan Orphan Drugs Market Overview |
3.1 Taiwan Country Macro Economic Indicators |
3.2 Taiwan Orphan Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Taiwan Orphan Drugs Market - Industry Life Cycle |
3.4 Taiwan Orphan Drugs Market - Porter's Five Forces |
3.5 Taiwan Orphan Drugs Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Taiwan Orphan Drugs Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 Taiwan Orphan Drugs Market Revenues & Volume Share, By Therapy Class, 2021 & 2031F |
4 Taiwan Orphan Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of rare diseases in Taiwan |
4.2.2 Growing awareness and advocacy for orphan drugs |
4.2.3 Favorable government policies and incentives to promote orphan drug development |
4.3 Market Restraints |
4.3.1 High costs associated with orphan drug research and development |
4.3.2 Limited patient pool for rare diseases in Taiwan |
4.3.3 Stringent regulatory requirements for orphan drug approval |
5 Taiwan Orphan Drugs Market Trends |
6 Taiwan Orphan Drugs Market Segmentations |
6.1 Taiwan Orphan Drugs Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Taiwan Orphan Drugs Market Revenues & Volume, By Revlimid, 2021-2031F |
6.1.3 Taiwan Orphan Drugs Market Revenues & Volume, By Rituxan, 2021-2031F |
6.1.4 Taiwan Orphan Drugs Market Revenues & Volume, By Opdivo, 2021-2031F |
6.1.5 Taiwan Orphan Drugs Market Revenues & Volume, By Keytruda, 2021-2031F |
6.1.6 Taiwan Orphan Drugs Market Revenues & Volume, By Imbruvica, 2021-2031F |
6.1.7 Taiwan Orphan Drugs Market Revenues & Volume, By Soliris, 2021-2031F |
6.2 Taiwan Orphan Drugs Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 Taiwan Orphan Drugs Market Revenues & Volume, By Biologics, 2021-2031F |
6.2.3 Taiwan Orphan Drugs Market Revenues & Volume, By Non-Biologics, 2021-2031F |
6.3 Taiwan Orphan Drugs Market, By Therapy Class |
6.3.1 Overview and Analysis |
6.3.2 Taiwan Orphan Drugs Market Revenues & Volume, By Oncology, 2021-2031F |
6.3.3 Taiwan Orphan Drugs Market Revenues & Volume, By Blood, 2021-2031F |
6.3.4 Taiwan Orphan Drugs Market Revenues & Volume, By Endocrine, 2021-2031F |
6.3.5 Taiwan Orphan Drugs Market Revenues & Volume, By Central Nervous Systems, 2021-2031F |
6.3.6 Taiwan Orphan Drugs Market Revenues & Volume, By Cardiovascular, 2021-2031F |
6.3.7 Taiwan Orphan Drugs Market Revenues & Volume, By Respiratory, 2021-2031F |
7 Taiwan Orphan Drugs Market Import-Export Trade Statistics |
7.1 Taiwan Orphan Drugs Market Export to Major Countries |
7.2 Taiwan Orphan Drugs Market Imports from Major Countries |
8 Taiwan Orphan Drugs Market Key Performance Indicators |
8.1 Number of patients diagnosed with rare diseases in Taiwan |
8.2 Government funding allocated for orphan drug research and development |
8.3 Number of orphan drug clinical trials initiated in Taiwan |
9 Taiwan Orphan Drugs Market - Opportunity Assessment |
9.1 Taiwan Orphan Drugs Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Taiwan Orphan Drugs Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.3 Taiwan Orphan Drugs Market Opportunity Assessment, By Therapy Class, 2021 & 2031F |
10 Taiwan Orphan Drugs Market - Competitive Landscape |
10.1 Taiwan Orphan Drugs Market Revenue Share, By Companies, 2024 |
10.2 Taiwan Orphan Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations | 13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here